Endo International plc obtained a preliminary injunction barring QuVa Pharma Inc. from selling a product that would compete with Endo's Vasostrict.
Endo subsidiaries Par Pharmaceutical Inc. and Par Sterile Products Inc. secured the preliminary injunction, which was issued by U.S. District Judge Brian Martinotti. The injunction is effective through the end of an as-yet unscheduled trial.
In its complaint, filed in the U.S. District Court for the District of New Jersey in August 2017, Par alleged that its trade secrets were misappropriated by QuVa and other defendants in relation to QuVa's development of a vasopressin product.
Endo's Vasostrict, a vasopressin injection, is used to increase blood pressure in adults with reduced blood pressure
Dublin's Endo International develops drugs for pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and cardiovascular diseases.
